InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-17.7%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by New Enterprise Associates 17, L.P.. Director active across 5 companies, notably Monte Rosa Therapeutics, Inc.. In total, 6 reports have been recorded. Split: 2 buys · 0 sell. Total volume traded: €2.9m. Activity tracked since 22 April 2024. The latest transaction was filed on 10 March 2026 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to New Enterprise Associates 17, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
207,100 shares@ US$11.1167.8% of flowCommon StockSEC:0001193125-26-104719:0
Canonical exit: 8 Jun 2026 (T+90)
1,619,240 sharesCommon StockSEC:0001193125-26-046671:0
189,195 shares@ US$0.01100.0% of flowCommon StockSEC:0001193125-25-232131:0
1,023,103 sharesCommon StockSEC:0000950170-24-107537:0
17,857 shares@ US$56.00100.0% of flowCommon StockSEC:0000950170-24-047686:0
Canonical exit: 21 Jul 2024 (T+90)
2,715,968 sharesCommon StockSEC:0001209191-21-044033:0
6 of 6 declarations
About New Enterprise Associates 17, L.P.
New Enterprise Associates 17, L.P. is a declarant with 4 filings in total. In the 4 sampled recent filings, the only quantified transaction is a buy of EUR 938602, and the period covered runs from 2021-06-30 to 2024-09-17. The companies mentioned are Monte Rosa Therapeutics, Inc., MBX Biosciences, Inc. and Korro Bio, Inc.
